Psychiatric diagnosis

US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder.

Retrieved on:

Tuesday, July 27, 2021

Psychiatric diagnosis, Mind, Self, Psychology, Major depressive disorder, Depressive, Depression, United States Patent and Trademark Office

The patent covers both the formulation of NRGBiotic and a method for treating, preventing, or ameliorating at least one symptom of depression or a depressive disorder and is valid through to 28 October 2035.

Key Points:

The patent covers both the formulation of NRGBiotic and a method for treating, preventing, or ameliorating at least one symptom of depression or a depressive disorder and is valid through to 28 October 2035.
Dr Sean Hall, CEO of Medlab stated the USPTO decision to allow is welcoming news.
NRGBiotic has both the formulation and capabilities of that formulation previously approved in Australia.
From a commercial aspect, NRGBiotic is a branded line here in Australia, and will now go to our partnering network in the Northern Hemisphere.

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on:

Tuesday, July 27, 2021

Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.

Key Points:

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

Memory Health Receives Third Patent For Role In The Prevention And/Or Treatment Of Neurodegenerative Disease

Retrieved on:

Tuesday, July 27, 2021

Branches of biology, Cognitive disorders, Psychiatry, Neuroscience, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, Neurodegeneration, Mild cognitive impairment, Disabilities affecting intellectual abilities, Neuroscience of aging

The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.

Key Points:

The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.
Memory Health is the only supplement patented specifically for the prevention and/or treatment of neurodegenerative disease.
The term Neurodegenerative disease describes a range of conditions such as memory loss, mild cognitive impairment, dementia, and Alzheimer's disease, primarily affecting the neurons in the human brain.
Memory Health is the gold standard of brain supplementation, the only patented formula for the prevention and/or treatment of neurodegenerative disease, especially dementia, in human subjects.

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on:

Tuesday, July 27, 2021

Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ -- Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050. Meanwhile, anticipated trends in smoking, high body mass index and high blood sugar are predicted to increase prevalence by nearly the same number: 6.8 million cases. Both according to new global prevalence data reported at the Alzheimer's Association International Conference® (AAIC®) 2021 in Denver and virtually.

Key Points:

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

Psychedelics -- Not Just for Mental Health Anymore

Retrieved on:

Tuesday, July 27, 2021

Psychiatry, Psychiatric diagnosis, Branches of biology, Psychology, Abnormal psychology, Mental disorder, Attention deficit hyperactivity disorder, Post-traumatic stress disorder, Freedom from fear

The majority of companies in the psychedelic space are pursuing mental illnesses, with a particular affinity for depression.

Key Points:

The majority of companies in the psychedelic space are pursuing mental illnesses, with a particular affinity for depression.
Many companies in the psychedelics space are leveraging data (historical, recent and anecdotal) that suggest psychedelics can be beneficial for mental disorders and diseases.
These indications include post-traumatic stress disorder (PTSD), anxiety, attention deficit-hyperactivity disorder, (ADHD) and different types of depression, to name a few mental illness targets.
The German biotech is a holding company for several start-ups conducting research with psychedelics for various mental illnesses.

Psychedelics -- Not Just for Mental Health Anymore

Retrieved on:

Tuesday, July 27, 2021

Psychiatry, Psychiatric diagnosis, Branches of biology, Psychology, Abnormal psychology, Mental disorder, Attention deficit hyperactivity disorder, Post-traumatic stress disorder, Freedom from fear

NEW YORK, July 27, 2021 /PRNewswire/ -- In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing therapies for hard-to-treat diseases. In November 2013, Gazyva, a drug used in combination with chlorambucil for patients with chronic lymphocytic leukemia, made history as the first breakthrough therapy to receive FDA marketing approval. Since then, hundreds of drugs have earned the designation, and several have reached commercialization. An area that remains underrepresented on the FDA breakthrough therapy list that could make waves in the coming years is that of the emerging market of psychedelics, where companies such as Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is striving to provide relief for patients with chronic pain by developing evidence-based innovation in areas where today's approved drugs and therapies are lacking. Tryp is part of a select group of companies that are advancing or have already advanced psychedelic treatments into Phase 2 of the FDA clinical trial process, a small collection of impressive companies that includes COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), ATAI Life Sciences N.V. (NASDAQ: ATAI) and Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF).

Key Points:

The majority of companies in the psychedelic space are pursuing mental illnesses, with a particular affinity for depression.
Many companies in the psychedelics space are leveraging data (historical, recent and anecdotal) that suggest psychedelics can be beneficial for mental disorders and diseases.
These indications include post-traumatic stress disorder (PTSD), anxiety, attention deficit-hyperactivity disorder, (ADHD) and different types of depression, to name a few mental illness targets.
The German biotech is a holding company for several start-ups conducting research with psychedelics for various mental illnesses.

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Retrieved on:

Monday, July 26, 2021

Branches of biology, Life sciences, Amyloidosis, Biology, Cognitive disorders, Alzheimer's disease, Learning disabilities, Psychiatric diagnosis, Biogen, Eisai, Aducanumab, Dementia

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points:

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

Retrieved on:

Monday, July 26, 2021

Branches of biology, Biology, Neuroscience, Biomarkers, Psychiatric diagnosis, Neurology, Myelin, Axon, Alzheimer's disease, Neuroinflammation, Wallerian degeneration

Boca Raton, FL, July 26, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD). The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.

Key Points:

The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.
"This is the first time in my career that I have seen positive changes, and in such a short time frame.
"Apparent fiber density decreases with axonal degeneration, and this is always seen in Alzheimer's disease patients.
In the Phase 1b study, we demonstrated XProTM significantly decreased biomarkers of neuroinflammation in Alzheimers patients.

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Retrieved on:

Monday, July 26, 2021

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points:

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.

Lighthouse Autism Center and Cerberus Announce Strategic Partnership

Retrieved on:

Monday, July 26, 2021

Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.

Key Points:

Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.
Lighthouse is a leading provider of center-based applied behavioral analysis (ABA) services for children diagnosed with autism spectrum disorder.
Nicholas Scola, Partner at Abry Partners, added: "We are excited to continue our partnership with the Lighthouse team and welcome the support of Cerberus.
Headquartered in South Bend, Indiana, Lighthouse is a leading provider of center-based autism behavioral health services for children diagnosed with autism spectrum disorder.